BRINERDINE TABLETS

Indications

• Cognitive enhancement in age-related cognitive decline
• Alzheimer's disease

Dosage

Children: Refer to the BNF for Children for paediatric dosing information.

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

Dihydroergocristine's mechanism of action is related to its noncompetitive antagonistic activity at serotonin receptors and partial agonist/antagonist activity at dopaminergic and adrenergic receptors. Additionally, it acts as a direct inhibitor of γ-secretase in Alzheimer's studies.

Pharmacodynamics

Dihydroergocristine has been reported to enhance memory and cognitive functions by increasing glutathione levels in the brain. It exhibits effects on serotonin and adrenergic receptors, which also correlate with inhibition of platelet aggregation. The drug has amphoteric vasoregulating activity, acting as a hypotensive agent in hypertensive individuals and as a hypertensive agent in hypotensive individuals. This dual action promotes vasodilation in contracted arteries while providing tonic support in dilated arteries, leading to increased cerebral blood flow and oxygen consumption, thereby protecting brain function.

Pharmacokinetics

Information on the pharmacokinetics of dihydroergocristine is not provided, including absorption, distribution, metabolism, and excretion details. For specific pharmacokinetic parameters, consult relevant literature or resources.

Pregnancy

Dihydroergocristine should be used with caution during pregnancy. Consult healthcare providers for risk assessment and advice.

Breast-feeding

Caution is advised when using dihydroergocristine while breastfeeding. Consult healthcare providers for recommendations.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Indications

• Hypertension
• Edema associated with heart failure
• Fluid retention

Dosage

Children: Refer to specific dosing guidelines for individual

Adults: Refer to specific dosing guidelines for individual components and patient circumstances.

Mechanism of action

Reserpine works by inhibiting the uptake of catecholamines (norepinephrine, dopamine) into storage vesicles in adrenergic neurons, leading to a depletion of these neurotransmitters in the central nervous system. This results in reduced sympathetic nervous system activity, which lowers blood pressure. Clopamide, a thiazide-like diuretic, inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, leading to increased excretion of sodium and water, thus reducing blood volume and blood pressure.

Pharmacodynamics

The pharmacodynamic effects of mesilatereserpineclopamide include vasodilation due to decreased sympathetic outflow and diuresis from the inhibition of sodium reabsorption. The combination of these effects results in a significant reduction in systemic vascular resistance and blood pressure, with the diuretic component also addressing fluid overload conditions.

Pharmacokinetics

Mesilatereserpineclopamide's pharmacokinetics involve the absorption, distribution, metabolism, and excretion of its components. Reserpine is well absorbed after oral administration, with peak plasma concentrations occurring in a few hours. It is metabolized in the liver and has a long half-life, allowing for sustained effects. Clopamide, being a thiazide-like diuretic, also exhibits good oral bioavailability, is primarily excreted unchanged in the urine, and has a half-life that supports once-daily dosing. Both components may exhibit interactions with other drugs affecting their metabolism or renal excretion.

Contra-indications

• Hypersensitivity to mesilatereserpineclopamide or any of its components
• Severe cardiovascular disorders
• Severe hepatic impairment
• History of peptic ulcer disease
• Pregnancy

Adverse effects

• Drowsiness
• Dry mouth
• Dizziness
• Hypotension
• Gastrointestinal disturbances
• Weight gain
• Extrapyramidal symptoms

Interactions

• CNS depressants may enhance the sedative effects
• Antihypertensives may increase the risk of hypotension
• Anticholinergic drugs may antagonize the effects

Precautions

• Use with caution in patients with a history of depression
• Monitor blood pressure regularly due to potential hypotensive effects
• Caution in patients with a history of seizures or convulsions

Pregnancy

The use of mesilatereserpineclopamide during pregnancy is not recommended due to potential risks to the fetus.

Breast-feeding

It is not known whether mesilatereserpineclopamide is excreted in human milk. Caution is advised when administering to breastfeeding women.

Storage

Store in a cool, dry place, away from light. Keep out of reach of children.

Formulations

• Tablets
• Oral solution

Mechanism of action

Dihydroergocristine mechanism of action seems to be related to a noncompetitive antagonistic activity in the serotonin receptors as well as a double partial agonist/antagonist activity in dopaminergic and adrenergic receptors. In Alzheimer studies, dihydroergocristine act as a direct inhibitor of γ-secretase.

Pharmacodynamics

Dihydroergocristine has been shown to present effect on memory and cognition. This activity in the brain is been reported by an increase in glutathione in age-related brain states. The reported effect on serotonin and adrenergic receptors has also been correlated to an inhibition of platelet aggregation. It has also been reported that individuals exposed to dihydroergocristine may present an amphoteric vasoregulating activity either hypotensive in hypertensive individuals or hypertensive in hypotensive individuals. This action is performed by promoting a dilating action in the contracted arteries and a tonic action in the dilated arteries and arterioles. The vasoregulating effect causes an increase in cerebral blood flow and oxygen consumption by the brain, which correlates with the brain protective function of dihydroergocristine. In Alzheimer studies, dihydroergocristine reduced the amyloid-beta levels in different cell types. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit [DB01049].